Search

A novel CCOF core–shell composite material (S)-DTP-COF@SiO2 was prepared via asymmetric catalytic and in situ growth strategy. The prepared (S)-DTP-COF@SiO2 was utilized as separation medium for HPLC enantioseparation using normal-phase and reversed-phase chromatographic modes, which displays excellent chiral separation performance for alcohols, esters, ketones, and epoxides, etc. Compared with chiral commercial chromatographic columns (Chiralpak AD-H and Chiralcel OD-H columns) and some previously reported chiral CCOF@SiO2 (CC-MP CCTF@SiO2 and MDI-β-CD-modified COF@SiO2)-packed columns, there are 4, 3, 13, and 15 tested racemic compounds that could not be resolved on the Chiralpak AD-H column, Chiralcel OD-H column, CC-MP CCTF@SiO2 column, and MDI-β-CD-modified COF@SiO2 column, respectively, which indicates that the resolution effect of (S)-DTP-COF@SiO2-packed column can be complementary to the other ones. The effects of the analyte mass, column temperature, and mobile phase composition on the enantiomeric separation were investigated. The chiral column exhibits good reproducibility after multiple consecutive injections. The RSDs (n = 5) of the peak area and retention time were less than 1.5% for repetitive separation of 2-methoxy-2-phenylethanol and 1-phenyl-1-pentanol. The chiral core–shell composite (S)-DTP-COF@SiO2 exhibited good enantiomeric separation performance, which not only demonstrates its potential as a novel CSP material in HPLC but also expands the range of applications for chiral COFs. [ABSTRACT FROM AUTHOR]

Delayed sleep-wake phase disorder (DSWPD) is common and easily misdiagnosed in young people, and to date, there is no evidence-based treatment. A nonblinded randomized controlled study evaluated the effect of agomelatine therapy (AT) and cognitive behavior therapy (CBT) on DSWPD in young adults. Sixty adolescents and young adults (range = 19–24 years, mean = 22 years, 52% female) diagnosed with DSWPD were randomized to receive 4 weeks of agomelatine therapy with or without cognitive behavior therapy. Sleep diaries, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), and World Health Organization wellbeing questionnaire (WHO-5) were measured pre-treatment and post-treatment. Agomelatine therapy for 4 weeks shifted the sleep-wake rhythm (p <.001) forward in both groups at the week 4 assessment. There were no significant differences in sleep onset (p =.099) and sleep offset (p =.959) between the CBT group and the no treatment (NT) group at the follow-up visits. However, significant differences were found in sleep duration (p =.002), sleep quality (p=0.005), sleep difficulties (p <.001), daytime sleepiness (p =.001), and wellbeing (p =.007) between groups. The improvements were received largely through the sleep-promoting effects of agomelatine therapy, and combining with cognitive behavior therapy on maintenance of altered sleep rhythms might be feasible. [ABSTRACT FROM AUTHOR]

Chiral covalent triazine frameworks (CCTFs), as emerging chiral organic porous polymer materials, have many special properties, such as being rich in nitrogen, having a large surface area, adjustable porosity, and high chemical stability, etc., making them an attractive separation medium for HPLC enantioseparation. Herein, a novel chiral core–shell composite CC-DMP CCTF@SiO2 with uniform spherical particles was synthesized by an in situ growth method. The prepared chiral core–shell microspheres CC-DMP CCTF@SiO2 were adopted to resolve chiral compounds by HPLC. The results showed that the CC-DMP CCTF@SiO2 packed column exhibited good separation performance and high column efficiency (e.g., 17 580 plates m−1 for 4-methylbenzhydrol) under a low column back pressure (5–9 bar) for HPLC separation of different chiral compounds such as alcohols, amines, ketones, and so on. Among them, the resolution values of naringenin and 1-phenyl-1,2-ethanediol were 4.24 and 4.09, respectively. Comparing the chiral recognition capacity of the CC-DMP CCTF@SiO2 packed column with those of commercial Chiralpak AD-H and the previously reported CCOFs@SiO2 (CTpBD@SiO2, β-CD-COF@SiO2) columns, the CC-DMP CCTF@SiO2 packed column can be complementary to the Chiralpak AD-H and CCOFs@SiO2 columns. The effects of the injection amount and column temperature on the separation process were also studied. The CC-DMP CCTF@SiO2 packed column exhibited good reproducibility and stability after multiple injections. The relative standard deviations (RSDS) of the retention time and peak area for repeated separation of 4-methylbenzhydrol (n = 5) were 0.45% and 0.87%, respectively. This work suggests that the chiral CC-DMP CCTF@SiO2 core–shell microsphere composite has a promising application as a novel CSP material in HPLC. [ABSTRACT FROM AUTHOR]

Coronavirus disease 2019 (COVID-19) first broke-out in Wuhan China in December 2019, and spread throughout the entire country within a short time. This cross-sectional study investigated the prevalence of depression and anxiety and associated risk factors were analysed in patients with COVID-19. This single-center cross-sectional study focussed on measuring depression and anxiety using self-report scales. Linear regression was used to determine independent predictors for depression and anxiety. A total of 78 patients who were confirmed to have COVID-19 were enrolled in the study. Prevalence of depression and anxiety symptoms were diagnosed in 35.9% and 38.5% of the patients, respectively. Multivariate linear regression analysis found female gender was an independent predictor for higher depression severity index. Having family members who were diagnosed with COVID-19 and family members who died from COVID-19 were independently associated with higher depression severity index and anxiety score. Patients with COVID-19 especially those who had family members diagnosed with COVID-19 or died from COVID-19 were more susceptible to depression and anxiety than were other patients. Effective strategies should be pursued to improve the mental health of this patient population. Patients with COVID-19 showed a significantly high prevalence of depression and anxiety. Female patients were associated with higher risk of depression. Patients with family members diagnosed as COVID-19 or died from this disease were associated with higher risk of depression and anxiety. [ABSTRACT FROM AUTHOR]